LandBridge Company LLC shares surged more than 6% in morning trading Friday, climbing to $68.05 as investors bet on the Permian Basin land owner’s growing role in powering the artificial intelligence data center explosion through strategic leasing deals and its vast surface acreage.

The Houston-based company, listed on the NYSE as LB, added $4.02, or 6.28%, by 11:26 a.m. EDT. The move came amid renewed enthusiasm for infrastructure plays tied to surging electricity demand from hyperscalers, following LandBridge’s early April announcement of a major lease development agreement that could unlock gigawatt-scale data center development on its West Texas holdings.

LandBridge owns or manages more than 315,000 surface acres, primarily in the heart of the Delaware sub-basin of the Permian, one of the most active oil and gas regions in the United States. Unlike traditional mineral royalty owners, the company focuses on surface rights, generating high-margin revenue from easements, surface use royalties, resource sales including produced water, and other land-related fees that support energy and industrial development.

The latest catalyst was the April 2 announcement of a lease development agreement with PowerBridge LLC. The deal grants PowerBridge the option to lease up to approximately 3,400 acres in Reeves County, Texas, for the Alpha Digital Campus — a giga-scale data center project with up to 2 GW of initial co-located power generation. PowerBridge has already filed a Generation Interconnection Request and ordered long-lead equipment, with first power potentially online in 2027 and large-scale generation following in 2028, subject to regulatory approvals and commercial agreements.

“This agreement represents a catalyst for executing on the West Texas data center thesis,” LandBridge CEO Jason Long said in the release, highlighting the site’s proximity to the Waha natural gas hub, which offers strategic advantages for power generation. The project aligns with broader industry efforts to address power constraints for AI training clusters, where data centers require massive, reliable electricity supplies often co-located with generation assets.

The news built on earlier momentum. In February, following strong fourth-quarter and full-year 2025 results, LandBridge raised its quarterly dividend by 20% to $0.12 per share and authorized a $50 million share repurchase program. For fiscal 2025, the company reported revenue of $199.1 million, up 81% year-over-year, with adjusted EBITDA reaching $177.2 million. It guided for 2026 adjusted EBITDA between $205 million and $225 million, implying over 20% growth at the midpoint driven by continued surface activity and potential new infrastructure deals.

Q4 2025 revenue alone hit $56.8 million, a 56% increase from the prior year, with strong contributions from surface use royalties and easements. The business model is highly capital-efficient and asset-light, delivering adjusted EBITDA margins often exceeding 80-90% in recent periods because LandBridge collects fees without bearing drilling or heavy operating costs.

Analysts have responded positively to the data center pivot. Goldman Sachs raised its price target to $84 from $69 in March while maintaining a Buy rating, citing expectations for repeatable growth. Consensus targets hover around $76 to $78, with a generally Hold-to-Buy tilt across covering firms. Some forecasts point to earnings growth exceeding 100% in 2026 as new revenue streams materialize.

Beyond traditional oil and gas support, LandBridge has expanded into water management through its affiliate WaterBridge, which handles produced water volumes that reached millions of barrels per day in recent periods. Produced water royalties and sales provide recurring income less directly tied to commodity prices. The company has also explored solar, battery storage and other sustainable uses for its acreage.

The Permian data center narrative has gained traction as hyperscalers and power developers seek solutions to grid constraints and long interconnection queues. Texas’ independent grid and abundant natural gas resources make the region attractive for behind-the-meter or co-located power solutions. LandBridge’s holdings position it to benefit from land leases, easements and potential water supply for cooling — critical needs for large AI facilities.

Earlier partnerships, including discussions around gas-fired generation with players like NRG Energy, further illustrate the strategy. Management has described its acreage as a “perpetual call option” on growth opportunities in energy transition and digital infrastructure.

Financially, LandBridge maintains a solid position with low debt relative to cash flow. It closed a $500 million senior notes offering and established a new $275 million revolver in early 2026, enhancing liquidity for potential acquisitions or development support. Free cash flow for 2025 reached $122 million, supporting shareholder returns.

The company completed the acquisition of the 1918 Ranch, expected to add roughly $20 million to 2026 EBITDA. It also hosted an Investor Day in March, showcasing its macro outlook, valuation framework and growth pipeline across energy and digital infrastructure.

Challenges include execution risks on large projects, regulatory hurdles for power interconnections and data center entitlements, and commodity exposure in its legacy oil and gas royalties, though these represent a smaller portion of revenue. Gross margins remain exceptionally high due to the fee-based model, but scaling new initiatives will require careful capital allocation.

The stock has shown volatility typical of growth-oriented infrastructure names. It pulled back from earlier 2026 highs near $87 but has rebounded on data center news and broader AI sentiment. Friday’s trading volume appeared elevated as shares tested resistance levels following a recent dip.

Founded in 2021 by Five Point Infrastructure LLC, LandBridge went public in 2024 and has quickly established itself as a unique Permian play. With only a lean team of around 18 employees, it emphasizes active land management to maximize value from surface rights while fostering development that benefits operators and new industries.

Broader tailwinds include surging U.S. electricity demand from AI, manufacturing reshoring and electrification. Analysts project the data center power market to expand dramatically, creating opportunities for land owners who can offer scale, water access and proximity to fuel sources.

Q1 2026 earnings are expected around early May, where investors will seek updates on the PowerBridge project, water volumes, acquisition contributions and any additional M&A or leasing activity. Management has signaled a robust pipeline, including potential battery storage and further digital infrastructure deals.

As the AI infrastructure buildout accelerates, companies like LandBridge that control strategic acreage in energy-rich regions stand to benefit disproportionately. Its high-margin, recurring revenue profile combined with upside from transformative projects has drawn comparisons to other Permian royalty and land plays, though with a heavier emphasis on surface and non-traditional uses.

Friday’s rally reflected investor willingness to price in the long-term potential of data centers on Permian land, even as near-term revenue remains anchored in traditional energy support. With secured acreage, water resources and a track record of execution, LandBridge positions itself at the intersection of the energy transition and the digital economy.

Whether the Alpha Digital Campus and similar projects reach full scale will depend on power agreements, regulatory timelines and hyperscaler commitments. For now, the announcement has reignited excitement around LandBridge’s ability to monetize its land in novel, high-value ways.

Fabrinet shares surged more than 7% in morning trading Friday, climbing to $663.65 as investors rewarded the precision manufacturing specialist’s deepening role in powering artificial intelligence data centers through advanced optical components and expanded production capacity.

The Bangkok-based company, listed on the NYSE as FN, added $45.65, or 7.39%, by 11:32 a.m. EDT. The sharp gain extended a remarkable rally that has seen the stock more than double over the past year, driven by explosive demand for high-speed optical transceivers, data center interconnects and high-performance computing modules essential to scaling massive AI clusters.

Fabrinet provides advanced optical packaging and precision electro-mechanical manufacturing services to original equipment manufacturers of complex products. Its expertise in building sophisticated optical assemblies has positioned it as a critical link in the AI infrastructure supply chain, supplying components for hyperscalers, networking giants and leading photonics companies.

The latest momentum builds on strong fiscal second-quarter 2026 results released Feb. 2. Revenue hit a record $1.13 billion, up 36% from the year-ago period and 16% sequentially. Non-GAAP net income rose to $121.6 million, or $3.36 per diluted share, beating guidance and reflecting robust operating leverage.

Optical communications, which accounted for the majority of revenue, surged 29% year-over-year to about $833 million. Within that segment, telecom revenue jumped 66%, data center interconnect modules grew 42%, and high-performance computing revenue exploded from $15 million in the prior quarter to $86 million, tied to new programs including work with Amazon Web Services.

CEO Seamus Grady highlighted durable demand across telecom, datacom and HPC, with sequential acceleration expected in most major segments. The company guided for third-quarter revenue of $1.15 billion to $1.20 billion and non-GAAP EPS of $3.45 to $3.60, signaling continued hyper-growth as AI infrastructure spending remains elevated.

Fabrinet is aggressively expanding manufacturing footprint to meet demand. It is constructing Building 10 in Chonburi, Thailand — a 2-million-square-foot facility that will eventually add roughly $3 billion in annual revenue capacity when fully ramped. Initial phases are expected to come online through 2026, with additional conversions at its Pinehurst campus adding further space. Management estimates current capacity around $5.5 billion, with potential to reach $8.5 billion or more as new facilities mature, providing ample room for growth without immediate constraints.

A key recent catalyst came in mid-March when iPronics announced an expanded manufacturing partnership with Fabrinet. The deal adds a dedicated production line for silicon photonics-based optical circuit switching systems, critical for reducing latency and improving efficiency in large-scale AI networks. The line targets full operational readiness by the June 2026 quarter, positioning Fabrinet to capture share in this emerging high-margin technology.

The company also participated actively at the Optical Fiber Communication Conference 2026, webcasting investor and analyst Q&A sessions that underscored its role in co-packaged optics, optical circuit switching and next-generation interconnects. Demonstrations and customer engagements at the event reinforced confidence in sustained growth across AI-driven optical networking.

Analysts largely remain bullish. Consensus price targets cluster around $530 to $582, with some higher forecasts reaching $715, though the stock’s rapid run has pushed it well above many near-term targets. Ratings tilt heavily toward Buy, reflecting Fabrinet’s track record of beating expectations, strong customer relationships and exposure to secular AI tailwinds. Rosenblatt Securities, for instance, has maintained a Buy rating with a $550 target.

Gross margins and operating margins have held steady or improved slightly despite rapid scaling, thanks to favorable mix shifts toward higher-value AI-related programs and operational efficiencies. The company maintains a clean balance sheet with zero net debt, providing flexibility for continued capital investments and potential strategic moves.

Challenges include customer concentration risks, as a handful of large OEMs and hyperscalers account for a significant portion of revenue. Supply chain dynamics for advanced components can create short-term volatility, though management has noted easing constraints through new qualified sources. Capital expenditures have risen sharply to support capacity builds, temporarily pressuring free cash flow.

Broader industry tailwinds remain powerful. Hyperscalers continue committing hundreds of billions to AI data center expansion, driving unprecedented demand for high-bandwidth, low-power optical interconnects. Technologies like silicon photonics and co-packaged optics are seen as essential for overcoming power and latency bottlenecks in next-generation GPU clusters.

Fabrinet’s vertically integrated capabilities — from precision assembly to rigorous testing — allow it to deliver complex modules at scale with high quality, differentiating it from pure-play competitors. Its long-standing relationships with blue-chip clients, including those supplying Nvidia-based systems and major cloud providers, provide visibility into multi-year growth trends.

The stock has exhibited classic high-growth volatility, pulling back at times on valuation concerns or broader market swings but repeatedly finding support on positive AI news flow. Friday’s elevated volume suggested fresh buying interest amid sympathy moves with other AI infrastructure names and anticipation ahead of the fiscal third-quarter earnings report expected in early May.

Founded in 1999, Fabrinet has evolved from a contract manufacturer into a strategic partner for cutting-edge optical and electronic systems. It operates primarily in Thailand, leveraging skilled labor, cost efficiencies and proximity to Asian supply chains while maintaining rigorous quality standards demanded by global tech leaders.

In February, the company published its 2025 Corporate Responsibility Report, highlighting commitments to sustainable manufacturing, workforce development and ethical practices — factors increasingly important to customers in the ESG-focused tech sector.

As investors digest the latest surge, attention will turn to execution on capacity expansions, the iPronics silicon photonics ramp and any commentary on co-packaged optics adoption during the upcoming earnings call. Guidance for the remainder of fiscal 2026 could provide further clarity on whether current growth rates are sustainable or if margin pressures emerge from heavy investments.

Fabrinet’s story exemplifies the infrastructure layer of the AI revolution. While the stock trades at a premium valuation reflecting hyper-growth expectations, its demonstrated ability to scale production, win new programs and deliver consistent beats has built significant investor conviction.

With AI data center buildouts showing no signs of abating and optical technologies playing an ever-larger role in connecting massive compute clusters, Fabrinet appears well-positioned to sustain its upward trajectory. The coming quarters will test whether it can convert record backlog and capacity additions into sustained profitability and market share gains in this critical segment of the semiconductor and networking ecosystem.

Google has fired the opening shot in a battle for Britain’s restaurant booking market, rolling out an artificial intelligence tool that allows diners to secure a table without ever leaving the search bar.

The feature, which went live on Friday, invites users to describe the sort of meal they are after in plain language. Google’s AI then trawls the web for real-time availability and returns a shortlist of bookable options within seconds, collapsing what was once a multi-step hunt into a single query.

It represents a marked departure from the traditional search experience. Rather than directing punters off to comparison sites or third-party platforms, Google is now intent on keeping the entire customer journey, from the first idle thought about dinner through to a confirmed reservation, firmly within its own walls.

The Silicon Valley giant said appetite for smarter dining tools is growing sharply, pointing to a 140 per cent rise this year in search queries such as “when to book a table” as consumers demand faster and more tailored recommendations.

Listings will be drawn from partners including TheFork, Sevenrooms and DesignMyNight, yet the interface, and crucially the customer relationship, will sit squarely with Google. That raises awkward questions about who ultimately owns the diner and who profits from the transaction.

The move sets Google on a direct collision course with established players such as OpenTable, whose business has long depended on playing intermediary between restaurants and hungry customers. By intercepting users at the point of search and ushering them through to booking, Google threatens to disintermediate those platforms altogether and squeeze their margins in the process.

More broadly, the launch signals the dawn of a new phase in the AI race, one defined not by chatbots answering questions but by agents quietly completing tasks on the user’s behalf. The ultimate prize is a search engine that functions as a digital concierge, and for Google, controlling bookings delivers a rich seam of behavioural data that can be fed back into its advertising and recommendation machinery.

Britain, with its densely packed restaurant scene and enthusiastic take-up of online reservation platforms, offers an ideal proving ground before the technology is extended to adjacent sectors such as travel and live events. For the incumbents of the booking world, the writing may already be on the wall.

---

Railway infrastructure company Vishal Nirmiti has received approval from the capital markets regulator Sebi to launch its IPO, paving the way for the civil engineering and infrastructure player to tap the primary market. The IPO comprises a fresh issue of Rs 125 crore along with an offer for sale of up to 0.15 crore equity shares by existing shareholders. The shares are proposed to be listed on both the BSE and NSE.

The proceeds from the fresh issue are expected to be used primarily to fund working capital requirements and reduce debt, with Rs 65 crore earmarked for working capital and Rs 20 crore for loan repayment.

Incorporated in 1994, Vishal Nirmiti operates across manufacturing and EPC segments, with a strong focus on railway infrastructure.

The company manufactures pre-stressed concrete sleepers for railways and undertakes fabrication of mild steel pipes and related components for irrigation and hydro projects. It also executes EPC contracts across railways, renewable energy and industrial infrastructure.

The company has a pan-India presence with operational facilities across multiple states and is led by a promoter group with over four decades of industry experience.

Its business model spans both manufacturing of infrastructure components and execution of large-scale projects, providing diversification across revenue streams.
Financially, the company has reported strong growth, with revenue rising 31% and profit after tax jumping significantly in the last financial year, indicating improving operating leverage and execution momentum.

Crescent Investments and Forshaw Group scheme would include 814 homes

Three huge apartment blocks could soon be built next to the River Irwell in Salford. The scheme, tabled by Crescent Investments LLC Limited and Forshaw Group, would deliver 814 new homes to the area.

The site is called Riverside Place and was once home to McDonald’s, KFC, and a Grosvenor Casino. Permission for demolition of the retail park, off Regent Road and Ordsall Lane, was approved in 2023 and the land has long been earmarked for redevelopment.

The proposal would see one, two and three bedroom flats built across the three tower blocks that will be between 21 and 36 storeys in height.

The scheme also includes a two-storey community pavilion designed to accommodate a mix of commercial, retail, hospitality and community uses. All this will be built on 6,000sqm of newly created ‘high-quality’ public space.

The area would also see improved links between Salford Quays and Manchester city centre; better pedestrian and cycle routes; and a landscaped ramp and seating connecting directly to the waterfront.

The scheme is expected to create more than 1,000 jobs and £1.7m in council tax revenue to invest locally, according to developers.

The vision for the project read: “The plans for Riverside Place support Salford Council’s ambitions for high density, residential-led growth in the ‘Ordsall Waterfront area’ as set out in the Salford Local Plan (2023). The new development would contribute directly to the city’s goal of building 9,000 homes across Ordsall, Quays, Pendleton and Charlestown by 2042.

“The site also plays an important role in bringing to life Salford City Council’s Irwell River Park Connectivity and Movement Strategy (2025), by delivering part of an active travel route for both pedestrians and cyclists along the riverside – enhancing the corridor between Salford Quays and Manchester City Centre.”

If the plans are approved by Salford council, the phased construction is expected to take three to four years to be completed.

To find all the planning applications, traffic diversions, road layout changes, alcohol licence applications and more in your community, visit the Public Notices Portal.

MELBOURNE, Australia — Telix Pharmaceuticals Ltd. shares surged more than 7% Friday as the Australian radiopharmaceutical company received a key regulatory boost in the United States, highlighting its growing role in precision oncology diagnostics and therapeutics.

Telix (ASX: TLX) stock climbed A$1.00, or 7.33%, to A$14.64 by the close of trading on the Australian Securities Exchange at 4:16 p.m. GMT+10. The move extended gains that have seen the stock rise about 31% over the past month, fueled by robust commercial performance and pipeline advancements in the fast-expanding field of targeted radiopharmaceuticals.

The rally was triggered by Telix’s announcement that the U.S. Food and Drug Administration accepted its resubmitted New Drug Application for TLX101-Px, known as Pixclara (18F-FET), an imaging agent designed to improve diagnosis and management of glioma, the most common form of primary brain cancer. The FDA set a Prescription Drug User Fee Act target action date of Sept. 11, 2026, for the potential approval.

Pixclara aims to address limitations of current imaging techniques by providing better visualization of brain tumors, potentially aiding more accurate treatment planning for patients facing this aggressive disease. Telix also filed a Marketing Authorization Application for the product, branded Pixlumi in Europe, advancing its global regulatory strategy for the asset.

“This acceptance marks another important milestone as we work to bring innovative radiopharmaceutical solutions to patients with high unmet needs,” Telix executives noted in recent communications, emphasizing the company’s dual focus on diagnostics and therapeutics.

Telix specializes in developing and commercializing targeted radiopharmaceuticals that combine radioactive isotopes with molecules designed to bind to specific cancer markers. Its portfolio includes approved imaging agents and late-stage therapeutic candidates for prostate, kidney, brain and other cancers.

The company’s flagship products — Illuccix and Gozellix, both gallium-68 PSMA-PET imaging agents for prostate cancer — drove much of its recent growth. These tools help clinicians detect and stage prostate cancer more precisely than traditional methods, guiding decisions on surgery, radiation and systemic therapies.

In its Q1 2026 business update released earlier this week, Telix reported unaudited group revenue of US$230 million, up 11% from the previous quarter and 24% year-over-year. Precision Medicine revenue, which includes Illuccix and Gozellix sales, reached US$186 million, a 16% sequential increase, reflecting strong U.S. dose volume growth and international expansion.

The company reaffirmed its full-year 2026 revenue guidance of US$950 million to US$970 million, implying continued double-digit growth following 2025’s robust performance. For the full year 2025, Telix posted revenue of approximately US$803.8 million, a 56% jump from the prior year, driven by higher Illuccix volumes and the successful U.S. launch of Gozellix after securing reimbursement.

Analysts have responded positively. Wedbush maintained an Outperform rating with a US$22 price target, while H.C. Wainwright reiterated a Buy rating at US$20. Consensus targets hover around US$21, suggesting significant upside from current levels on both ASX and Nasdaq listings. Some forecasts point to potential revenue approaching US$1.5 billion by 2028 if pipeline assets reach commercialization.

Beyond diagnostics, Telix is advancing a therapeutics pipeline that could transform its business model from primarily imaging-focused to a balanced diagnostics-and-therapy player. Its lead candidate, TLX591 (lutetium-177 rosopatamab tetraxetan), is in the ProstACT Global Phase 3 trial for PSMA-positive metastatic castration-resistant prostate cancer.

Part 1 of the study, a lead-in safety and dosimetry evaluation, recently met its objectives with no new safety signals observed, supporting progression to the randomized portion. The therapy uses a radio-antibody drug conjugate approach to deliver targeted radiation directly to cancer cells while sparing healthy tissue.

Additional candidates include TLX250 for kidney cancer and TLX101 for brain cancer therapeutics, part of a strategy to pair diagnostic imaging with companion therapies — often called “theranostics” — in a single integrated approach.

Telix has invested heavily in manufacturing and supply chain capabilities to support growth. It operates facilities in key markets and has pursued strategic acquisitions to secure isotope supply and expand production. Year-end 2025 cash stood at US$141.9 million after significant investments, with ongoing R&D guidance for 2026 set at US$200 million to US$240 million.

The radiopharmaceutical sector has attracted intense investor interest amid breakthroughs in targeted cancer treatments. Major players and newcomers alike are racing to develop agents that improve outcomes while reducing side effects compared to traditional chemotherapy or broad radiation.

Telix’s vertically integrated model — spanning development, manufacturing and commercialization — positions it to capture more value across the supply chain. The company has expanded internationally, with operations in the United States, Europe, Japan, Brazil and elsewhere, and continues seeking approvals in additional markets for Illuccix and Gozellix.

Recent corporate moves include board strengthening with new non-executive director appointments and routine securities filings, including issuance of shares upon conversion of unquoted securities and notifications regarding substantial holders.

Despite the momentum, challenges remain. Radiopharmaceutical production involves complex logistics due to short isotope half-lives, requiring sophisticated cold-chain and just-in-time manufacturing. Regulatory hurdles can delay launches, as seen with previous FDA requests for additional data on certain assets. Competition is intensifying from larger pharmaceutical companies and specialized biotech firms entering the space.

Gross margins have held steady around 53% in recent periods, though increased R&D and commercial infrastructure spending have pressured adjusted EBITDA, which came in at US$39.5 million for 2025. Management has signaled a focus on scaling efficiently while prioritizing late-stage pipeline acceleration.

Market watchers note that success in the upcoming PDUFA date for Pixclara, combined with ProstACT data readouts, could serve as major catalysts. Positive outcomes might accelerate adoption of Telix’s platform and support premium valuations typical of high-growth biotech names with approved products and robust pipelines.

Founded in Melbourne, Telix has grown rapidly since its early days, transitioning from a development-stage company to one with commercial revenues and global reach. It maintains dual listings on the ASX and Nasdaq, broadening its investor base.

Broader industry tailwinds include rising cancer incidence, improved awareness of PSMA-PET imaging benefits, and policy support for innovative oncology therapies. Governments and payers increasingly recognize the value of precise diagnostics in reducing unnecessary procedures and optimizing treatment.

Friday’s trading volume on the ASX was elevated as investors digested the FDA news alongside the solid Q1 performance. Technical charts show the stock breaking out from recent consolidation, though it remains below all-time highs reached during earlier enthusiasm phases.

As Telix prepares for potential Pixclara approval later this year and further clinical data, attention will turn to execution on revenue guidance, margin trends and pipeline milestones. Analysts will scrutinize any commentary on manufacturing scale-up and international launches during future updates.

For now, the combination of commercial traction in prostate cancer imaging and progress toward brain cancer diagnostics has reignited optimism around Telix’s theranostics platform. With the global radiopharmaceutical market projected to expand significantly, the company appears well-placed to benefit from the shift toward personalized, targeted cancer care.